Service Oncology, AP-HP, Groupe Henri Mondor-Albert Chenevier, Creteil, France.
Anticancer Res. 2010 Dec;30(12):5165-8.
Bone is the second most common metastatic site in patients with renal cell carcinoma presenting with metastases (mRCC) at diagnosis. Complications of metastatic bone disease, including bone pain, fractures, spinal cord compression, and hypercalcaemia, are the primary cause of decline in the quality of life of patients with mRCC. Currently, treatment for mRCC bone metastases is generally palliative. Bisphosphonates are also used; however, the efficacy of bisphosphonates in conjunction with targeted agents is currently unknown. As growth factors play a critical role in the development of bone metastases, there is a biological rationale for the use of targeted agents to treat them. We report here the case of two patients with mRCC with surgically unresectable sacral bone metastases treated with sunitinib, who are still alive with long-term stabilization of metastases of 48 and 31 months. Results suggest targeted agents such as sunitinib may be an effective treatment for bone metastases.
在初诊时就发生转移（mRCC）的肾细胞癌患者中，骨骼是第二常见的转移部位。转移性骨病的并发症，包括骨痛、骨折、脊髓压迫和高钙血症，是 mRCC 患者生活质量下降的主要原因。目前，mRCC 骨转移的治疗一般是姑息性的。双膦酸盐也被使用；然而，双膦酸盐联合靶向药物的疗效目前尚不清楚。由于生长因子在骨转移的发展中起着关键作用，因此有生物学依据使用靶向药物来治疗它们。我们在此报告了两名接受舒尼替尼治疗的无法手术切除的骶骨转移 mRCC 患者的病例，他们的转移仍处于长期稳定状态，分别为 48 个月和 31 个月。结果表明，舒尼替尼等靶向药物可能是治疗骨转移的有效方法。
